Neuroprotection

British Medical Bulletin

Volumn 56, Issue 2, 2000, Pages 401-412

  Lees, Kennedy R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

BRAIN BLOOD FLOW; DRUG POTENCY; DRUG TOLERANCE; FIBRINOLYTIC THERAPY; HUMAN; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0033787273     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1258/0007142001903049     Document Type: Review

References (43)

1. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death
2. Excitatory amino acid antagonists and their potential for the treatment of ischaemic brain damage in man
3. Massive persistent release of excitatory amino acids following human occlusive stroke
4. Duration of glutamate release after acute ischemic stroke
5. Progression of ischaemic stroke and excitotoxic aminoacids
6. Clinical experience with excitatory amino acid antagonist drugs
7. Identification and pharmacological characterization of GV150526, a novel glycine antagonist as a potent neuroprotective agent
8. The glycine antagonist GV150526 protects somatosensory evoked potentials and reduces the infarct area in the MCAo model of focal ischemia in the rat
9. Safety and tolerability of 619C89 after acute stroke
10. Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke
11. Neuronal injury inhibitor, glutamate release inhibitor
12. A randomized trial of tirilizad mesylate in patients with acute stroke (RANTTAS)
13. Safety, pharmacokinetics and biological activity of enlimomab (anti-ICAM-1 antibody): An open-label, dose escalation study in patients hospitalized for acute stroke
14. The Enlimomab Acute Stroke Trial: Final Results
15. Termination of acute stroke studies involving selfotel treatment
16. Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist
17. Multinational randomised controlled trial of lubeluzole in acute ischaemic stroke
18. Lubeluzole treatment of acute ischemic stroke
19. Lubeluzole in acute ischemic stroke treatment: Lack of efficacy in a large phase III study with an 8-hour window
20. Clomethiazole Acute Stroke Study (CLASS): Results of a randomized, controlled trial of clomethiazole versus placebo in 1360 acute stroke patients
21. Stroke rehabilitation: Analysis of repeated Barthel index measures
22. Cerebral vascular accidents in patients over the age of 60, II: Prognosis
23. Diffusion-weighted MR imaging of acute stroke: Correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats
24. Pitfalls and potential of clinical diffusion-weighted MR imaging in acute stroke
25. Tissue plasminogen activator for acute ischemic stroke
26. Intravenous ancrod for treatment of acute ischemic stroke: The STAT study: A randomized controlled trial
27. Duration of neuroprotective treatment for ischemic stroke
28. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke
29. Stroke unit treatment - Long term effects
30. Thresholds in cerebral ischaemia. The ischaemic penumbra
31. Trials of streptokinase in severe acute ischaemic stroke (The Australian Streptokinase Trial)
32. Termination of trial of streptokinase in severe acute ischaemic stroke
33. Which targets are relevant for therapy of acute ischemic stroke?
34. Recommendations for standards regarding preclinical neuroprotective and restorative drug development
35. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke
36. Value of minimisation for treatment allocation in acute stroke trials
37. Power of treatment allocation by adaptive stratification in anacute stroke trial
38. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke
39. Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long term follow up study
40. Glucose potassium insulin infusions in the treatment of acute stroke patients with mild to moderate hyperclycemia: The Glucose Insulin in Stroke Trial (GIST)
41. The safety and tolerability of GV150526 (a glycine site antagonist at the NMDA receptor) in patients with acute stroke: Two double blind, randomised, placebo controlled, parallel group, ascending dose studies
42. The experiences of an acute stroke unit-implications for multicentre acute stroke trials
43. Glycine antagonist gavestinel in neuroprotection (GAIN international) in patients with acute stroke: A randomised controlled trial